What Does 99% Tranexamic Acid Actually Tell a Cosmetic Buyer

A supplier listing that says “99% tranexamic acid” gives a buyer a useful starting point, but it does not complete the specification. The number may describe an assay result for a particular lot, while leaving identity confirmation, test method, moisture, impurities, packaging and formulation behavior unanswered. For a cosmetic developer, those details determine whether two apparently similar powders are genuinely comparable.

This guide treats tranexamic acid as a procurement and formulation decision, not as a generic skin-brightening ingredient. The practical conclusion is simple: use 99% as a screening signal, then verify the identity and lot-specific evidence before comparing price or ordering production quantity.

Why this question matters now

Tranexamic acid appears across consumer skincare discussions, clinical literature and supplier catalogs. The commercial interest is understandable, but those sources answer different questions. A consumer may ask whether a 3% serum can be combined with another active. A formulator needs to know whether the raw material is the same chemical, whether the assay is reported on an as-is or dry basis, and whether the supplied lot can be reproduced at scale.

Recent discussions also show why the raw-material specification matters. Buyers and formulators repeatedly raise questions about water solubility, penetration, concentration, pH and documentation. Those are not minor details to be added after a purchase; they affect the choice between a dry powder, a pre-dissolved solution, a delivery system and a chemically modified derivative.

The clinical literature should be read with the same discipline. A 2024 pilot study evaluated finished cream and serum formulas containing 3% tranexamic acid together with niacinamide, hyaluronic-acid materials and, in the serum, ascorbyl glucoside. That is evidence about those finished formulas and their use conditions. It is not evidence that every 99% powder will perform identically in every base.

Start with identity before discussing purity

For an initial purchasing screen, the expected material is tranexamic acid, commonly identified as CAS 1197-18-8. The CAS number is an identity checkpoint, not a complete quality certificate. The buyer should compare the CAS number, chemical name, stated molecular formula, appearance and analytical method across the quotation, specification sheet, COA and label.

Do not silently merge free tranexamic acid with a derivative or a delivery format. Cetyl tranexamate, liposomal tranexamic acid and a pre-formulated serum may all be marketed around the same cosmetic concern, but they are not interchangeable raw materials. Their composition, assay basis, dispersibility and manufacturing controls can be different.

• Ask the supplier to confirm the exact material name and CAS number on the batch COA.
• Check that the product description, model number and packaging label refer to the same material.
• Treat “cosmetic grade” as a commercial classification that still requires a defined specification.
• If the supplier offers a derivative or encapsulated version, request a separate specification rather than comparing it with free tranexamic acid by headline purity alone.

What 99% should mean in a usable COA

A number without a method and basis is difficult to compare. The COA should identify the lot, test date or release date, specification limits, observed result and test method. For assay, ask whether the result is reported on an as-is basis or corrected for moisture. A 99% result on different analytical bases may not represent the same material balance. The exact test panel will depend on the intended use and the supplier’s quality system, but a serious first review normally covers the following:

• Identity: method and result, not only a product name.
• Assay or purity: numerical result, specification limit and analytical basis.
• Water or loss on drying: especially important when the material is sold as a dry powder.
• Related substances or specified impurities: method, limits and actual lot result where available.
• Residual solvents, heavy metals and microbiological limits when relevant to the intended product and market.
• Appearance, packaging configuration, storage conditions and retest or shelf-life information.

A supplier’s statement that a COA, MSDS or ISO certificate is “available” is not the same as receiving and reviewing the documents. Before approving a production supplier, request a recent lot COA and confirm that the lot number on the document matches the sample or commercial pack. Keep the document with the internal raw-material approval record.

Powder, solution and delivery system are different buying decisions

Dry tranexamic acid powder is usually the most straightforward format for a manufacturer that controls its own formulation and wants to normalize cost by active mass. It also requires the buyer to manage dissolution, addition order, pH adjustment, preservation and compatibility in the finished system.

A pre-dissolved concentrate may reduce handling work, but the buyer must know the active concentration, solvent or carrier, preservative system, water content and storage limits. Compare the active-equivalent cost rather than the price per kilogram of the supplied liquid. A liquid that contains 10% active is not directly comparable with a 99% powder on a price-per-kilogram basis.

Liposomal or other delivery-system products should be evaluated as formulated delivery materials. Ask for particle-size data, encapsulation or loading information, release or stability evidence and the complete excipient system if those claims matter to the project. A label that repeats “99%” does not tell the buyer whether the number refers to the chemical active, the total powder, or a supplier-defined assay basis.

Formulation fit is where the specification becomes practical

Tranexamic acid is commonly approached as a water-phase active, so the development team should confirm the intended phase, solubility behavior at the target concentration and the order of addition in the actual base. The relevant pH is the pH of the finished formula under the chosen test conditions, not a universal number copied from a supplier page.

The 2024 pilot study is a useful example of why context matters. Its cream and serum were not just tranexamic acid in water: both included 3% tranexamic acid and 5% niacinamide, while the serum also included vitamin C and several hyaluronic-acid materials. The study evaluated a defined product protocol for eight weeks. It should not be used to promise that 3% is the correct concentration for every product, or that a raw powder alone carries the same evidence.

During development, record at least the following for each trial:

• Target active concentration and whether it is calculated from assay or nominal weight.
• Addition phase, temperature and mixing time.
• Finished-formula pH, appearance and any precipitation or crystallization observed over time.
• Preservative challenge and microbiological results where applicable.
• Short-term and accelerated stability results using the same packaging intended for sale.

If the finished formula changes color, clarity or viscosity during storage, do not assume that the raw-material assay explains the problem. Check the full formula, packaging, water quality, processing history and storage conditions.

How to compare samples without over-reading them

A sample is a decision tool, not a substitute for supplier qualification. Use the same small protocol for every candidate so that the comparison is fair. Record the received lot number, pack condition, date opened and any visible differences in color, odor or particle size. Weigh the material using the same balance and prepare the same concentration in the same water or vehicle. If one supplier recommends a different process, record that as a process difference rather than quietly changing the comparison.

A bench result can answer practical questions: does the powder dissolve within the intended processing window, does it change the formula’s appearance, and does the finished sample remain uniform during the planned observation period? It cannot by itself prove long-term stability, microbiological safety, clinical performance or batch-to-batch consistency. Those questions require the appropriate stability, microbiological, analytical or clinical work.

Do not transfer medical evidence directly to a cosmetic raw material

Tranexamic acid is also a medicine used for bleeding control, and it has been studied in dermatology in oral and topical contexts. Those uses involve different routes, doses, patient selection and risk assessments. A cosmetic buyer should not use oral-drug evidence as a safety or efficacy shortcut for a topical raw material, and a supplier should not be allowed to turn a medical claim into an automatic cosmetic claim.

The dermatology literature supports continued interest in topical tranexamic acid, but it also contains different formulations and study designs. For a cosmetic project, the defensible claim is narrower: the ingredient has been investigated in topical formulations, while the performance and tolerability of the buyer’s own finished product still require formulation-specific evaluation and market-compliance review.

The most useful sample comparison combines three records: the physical sample result, the document review and the supplier’s response quality. A supplier that answers identity and assay-basis questions clearly is easier to qualify than one that only repeats “99% pure.” This does not prove that the first supplier is technically superior, but it gives the buyer a more auditable basis for the next stage.

The bulk-oriented Product ID 1601522955214 remains in the comparison table as a reference. The current product page did not expose a verifiable product image, so it is not presented as a media-backed product card until the exact listing becomes available again.

Current Alibaba sourcing examples

The following two listings are included as sourcing examples, not as quality rankings. Their platform information is time-sensitive and should be rechecked before a commercial order. Platform reviews, reorder rates and sold counts are marketplace signals; they do not replace a COA review, sample testing or supplier qualification.

Raw supplier page for the Yhealth listing: https://yhealth.en.alibaba.com/company_profile.html

Before issuing a purchase order, ask both suppliers for the exact lot COA, specification sheet, MSDS or SDS, packaging photographs, sample availability, lead time, storage conditions and confirmation of the material identity. The two listings should be treated as separate offers; do not assume that matching headline purity means matching impurity profile or process control.

A practical RFQ checklist

A useful tranexamic acid RFQ is short enough to answer and specific enough to prevent non-comparable quotes. Ask the supplier to respond against the same fields:

• Exact product name, CAS number and intended grade.
• Assay method, assay basis and typical lot result.
• Water or loss-on-drying limit and typical result.
• Related-substance or impurity limits.
• Residual-solvent, heavy-metal and microbiology information where required.
• MOQ, sample quantity, production lead time and packaging.
• Storage, retest or shelf-life conditions and document issue date.
• Whether the quoted material is free tranexamic acid, a derivative, a delivery system or a pre-dissolved solution.

When the replies arrive, normalize them into one comparison sheet. Keep “not stated” as a visible value. A missing field is a procurement risk, not a reason to fill the gap with an assumption.

Bottom line

For cosmetic buyers, 99% tranexamic acid is a useful first filter, not a purchasing conclusion. The responsible sequence is identity, method and lot evidence, format, formulation fit, sample evaluation and then price. A lower-MOQ listing may be useful for an early bench trial, while a more established supplier may be more suitable for a larger RFQ; neither role removes the need for technical documentation.

The strongest buying decision is therefore not “which listing has the highest purity?” It is “which supplier can provide a clearly identified material, a comparable lot-specific COA and a format that behaves predictably in the finished formula?” That is the question a 99% headline cannot answer on its own.

References

• Gaćina K, Krstanović Ćosić A. The Use of Tranexamic Acid in Dermatology. Acta Clinica Croatica. 2023. Academic source
• Hsin S et al. Pilot Clinical Safety and Efficacy Evaluation of a Topical 3% Tranexamic Acid Cream and Serum Protocol for Managing Facial Hyperpigmentation in Caucasian Patients. Cosmetics. 2024;11(5):168. Academic source
• Kamal SM et al. Efficacy and Safety of Topical Tranexamic Acid Alone or in Combination with Other Therapies for Melasma. Dermatology Practical & Conceptual. 2023. Academic source
• Ejaz A et al. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. Journal of Cutaneous and Aesthetic Surgery. 2019. Academic source
• Sarkar R et al. Topical and Systemic Therapies in Melasma. Indian Journal of Dermatology. 2023. Academic source